article thumbnail

CMS Touts First Negotiated Drug Prices, But Greater Impact Expected in Future Rounds

MedCity News

The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026. Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come.

article thumbnail

MedTech Marketing 101: Your guide to high-impact campaigns

Clear Pivot

Companies must create unique and reliable products in order to stand out amongst the growing competition. billion by 2026 , so take the steps to create a successful medtech marketing strategy now as the industry is still growing. Revenue from the medical technology industry is projected to reach $644.20

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sandoz to build biologics plant in Slovenia

European Pharmaceutical Review

“Not only does the location has offer competitive costs [but it has] proximity to our existing European-based production and commercial operations.” Full operations is provisionally planned for late 2026. The new plant will support the growing biosimilars sector. Work on the biologics plant in Slovenia is set to begin this year.

article thumbnail

Novartis completes Sandoz spin-off

European Pharmaceutical Review

Sandoz – advancing biosimilar development in Europe Prior to the proposed spin-off being actioned, Sandoz announced in July 2023 that it planned to invest approximately $90 million to build a Biosimilar Technical Development Center in Slovenia by 2026. This is about 25 percent of the total cost.

Medicine 105
article thumbnail

Sandoz to build Slovenian biosimilar development facility

European Pharmaceutical Review

The company intends to invest approximately $90 million at its site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026. They drive competition and cost savings, helping to address the rising financial pressures faced by global healthcare systems.

article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

They do not have biosimilar or generic competition available in the market. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list.

article thumbnail

EU tax compliance proposals to streamline business investment

European Pharmaceutical Review

Ultimately, this puts European businesses at a competitive disadvantage compared to other companies worldwide. Once adopted by the Council, the regulatory proposals are planned to come into force on 1 July 2028 (for BEFIT) and on 1 January 2026 (for the transfer pricing proposal).